Skip to main content

Advertisement

SpringerLink
Log in

Gastric cancer: surgery in 2011

  • Review Article
  • Published:
Langenbeck's Archives of Surgery Aims and scope Submit manuscript

Abstract

Background

Treatment of gastric cancer is more and more becoming an individualized decision. The choice of the optimal approach is based on prognostic factors, on the anatomic site of the tumor, and on expectations about the response to neoadjuvant treatment. Early gastric cancer that is limited to the mucosal layer is the domain of endoscopic resections. As soon as the submucosal layer is invaded, surgical strategies with adequate lymphadenectomy become necessary.

Discussion

In many East Asian Centers and some other centers in the world, these tumors are resected by a laparoscopic approach. With a high experience, this can be done with excellent quality and outcome. In locally advanced gastric cancer, multimodal treatment can improve survival in comparison to surgery alone. However, the strategies differ significantly around the world. While adjuvant chemoradiotherapy is standard in the USA, in Europe, perioperative chemotherapy is the first choice, and in Japan, adjuvant chemotherapy is recommended. In Europe, three randomized phase III studies on the value of preoperative chemotherapy have been performed. Two of them have shown that perioperative chemotherapy does significantly improve the survival of patients with adenocarcinoma of the stomach and of the esophagogastric junction. The one including only preoperative chemotherapy failed to show a survival benefit for the combined treatment arm but showed excellent outcomes in both the surgery alone and the preoperative chemotherapy arms. Based on these studies, patients with stage II or stage III disease are now treated with perioperative chemotherapy. Additionally, it is generally accepted for more than 10 years now that responding patients have a significantly improved prognosis compared to nonresponding patients. The percentage of responding patients varies depending on the applied regimen between 20% and 45%. Therefore, early response evaluation or response prediction is an utmost important field of research. Proximal tumors are treated with a transhiatal extended gastrectomy, tumors in the middle third with a total gastrectomy, and distal tumors with a subtotal gastrectomy, if possible. Modified D2 lymphadenectomy avoiding splenectomy is now accepted as the standard procedure, providing improved prognosis for certain subgroups of patients. Individualized resection and lymphadenectomy techniques for early tumor stages and response-based neoadjuvant concepts for locally advanced tumors are the challenge for the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Monig SP, Schroder W, Baldus SE, Holscher AH (2002) Preoperative lymph-node staging in gastrointestinal cancer—correlation between size and tumor stage. Onkologie 25(4):342–344

    Article  PubMed  CAS  Google Scholar 

  2. Kitagawa Y, Kitajima M (2006) Gastroesophageal carcinoma: individualized surgical therapy. Surg Oncol Clin N Am 15(4):793–802. doi:10.1016/j.soc.2006.07.010

    Article  PubMed  Google Scholar 

  3. Schuhmacher CP, Fink U, Becker K, Busch R, Dittler HJ, Mueller J, Siewert JR (2001) Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer 91(5):918–927. doi:10.1002/1097-0142(20010301)91:5<918::AID-CNCR1081>3.0.CO;2-W

    Article  PubMed  CAS  Google Scholar 

  4. Ott K, Sendler A, Becker K, Dittler HJ, Helmberger H, Busch R, Kollmannsberger C, Siewert JR, Fink U (2003) Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 6(3):159–167. doi:10.1007/s10120-003-0245-4

    Article  PubMed  CAS  Google Scholar 

  5. Barbour AP, Rizk NP, Gerdes H, Bains MS, Rusch VW, Brennan MF, Coit DG (2007) Endoscopic ultrasound predicts outcomes for patients with adenocarcinoma of the gastroesophageal junction. J Am Coll Surg 205(4):593–601. doi:10.1016/j.jamcollsurg.2007.05.010

    Article  PubMed  Google Scholar 

  6. Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, Schwaiger M, Fink U (2003) FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 30(2):288–295. doi:10.1007/s00259-002-1029-5

    Article  PubMed  CAS  Google Scholar 

  7. Herrmann K, Ott K, Buck AK, Lordick F, Wilhelm D, Souvatzoglou M, Becker K, Schuster T, Wester HJ, Siewert JR, Schwaiger M, Krause BJ (2007) Imaging gastric cancer with PET and the radiotracers 18 F-FLT and 18 F-FDG: a comparative analysis. J Nucl Med 48(12):1945–1950. doi:10.2967/jnumed.107.044867

    Article  PubMed  CAS  Google Scholar 

  8. Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, Buck AK, Dobritz M, Fink U, Ulm K, Schuster T, Schwaiger M, Siewert JR, Krause BJ (2008) Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res 14(7):2012–2018. doi:10.1158/1078-0432.CCR-07-0934

    Article  PubMed  CAS  Google Scholar 

  9. Rosenberg R, Nekarda H, Bauer P, Schenck U, Hoefler H, Siewert JR (2006) Free peritoneal tumour cells are an independent prognostic factor in curatively resected stage IB gastric carcinoma. Br J Surg 93(3):325–331. doi:10.1002/bjs.5196

    Article  PubMed  CAS  Google Scholar 

  10. Feussner H, Hartl F (2006) Staging laparoscopy in oncology. Chirurg 77(11):971–980. doi:10.1007/s00104-006-1259-3

    Article  PubMed  CAS  Google Scholar 

  11. Lorenzen S, Panzram B, Rosenberg R, Nekarda H, Becker K, Schenk U, Hofler H, Siewert JR, Jager D, Ott K (2010) Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric carcinoma undergoing potentially curative resection. Ann Surg Oncol 17(10):2733–2739. doi:10.1245/s10434-010-1090-4

    Article  PubMed  Google Scholar 

  12. Burian M, Stein HJ, Sendler A, Feith M, Siewert JR (2004) Sentinel lymph node mapping in gastric and esophageal carcinomas. Chirurg 75(8):756–760. doi:10.1007/s00104-004-0909-6

    Article  PubMed  CAS  Google Scholar 

  13. Burian M, Stein HJ, Sendler A, Piert M, Nahrig J, Feith M, Siewert JR (2004) Sentinel node detection in Barrett’s and cardia cancer. Ann Surg Oncol 11(3 Suppl):255S–258S

    PubMed  Google Scholar 

  14. Roder JD, Bottcher K, Siewert JR, Busch R, Hermanek P, Meyer HJ (1993) Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. Cancer 72(7):2089–2097

    Article  PubMed  CAS  Google Scholar 

  15. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11–20. doi:10.1056/NEJMoa055531

    Article  PubMed  CAS  Google Scholar 

  16. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345(10):725–730. doi:10.1056/NEJMoa010187

    Article  PubMed  CAS  Google Scholar 

  17. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357(18):1810–1820. doi:10.1056/NEJMoa072252

    Article  PubMed  CAS  Google Scholar 

  18. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM (2010) Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for research and treatment of cancer randomized trial 40954. J Clin Oncol 28:5210–5218. doi:10.1200/JCO.2009.26.6114

    Article  PubMed  Google Scholar 

  19. Siewert JR, Schuhmacher C, Fink U (1998) The German EORTC Study of neoadjuvant therapy of stomach carcinoma. Langenbecks Arch Chir Suppl Kongressbd 115:717–719

    PubMed  CAS  Google Scholar 

  20. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA (1999) Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 229(3):303–308

    Article  PubMed  CAS  Google Scholar 

  21. Fink U, Schuhmacher C, Stein HJ, Busch R, Feussner H, Dittler HJ, Helmberger A, Bottcher K, Siewert JR (1995) Preoperative chemotherapy for stage III–IV gastric carcinoma: feasibility, response and outcome after complete resection. Br J Surg 82(9):1248–1252

    Article  PubMed  CAS  Google Scholar 

  22. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D’Adamo D, O’Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP (2006) Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24(33):5201–5206. doi:10.1200/JCO.2006.08.0887

    Article  PubMed  CAS  Google Scholar 

  23. Becker K, Fink U, Ott K, Busch R, Siewert JR, Hofler H (2001) How can the effectiveness of multimodality therapy concepts be evaluated? From the viewpoint of the pathologist. Kongressbd Dtsch Ges Chir Kongr 118:58–62

    PubMed  CAS  Google Scholar 

  24. Fink U, Ott K, Weber W, Siewert JR (2002) Neoadjuvant therapeutic principles guided by response prediction and evaluation. Kongressbd Dtsch Ges Chir Kongr 119:829–833

    PubMed  CAS  Google Scholar 

  25. Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, Stein H, Lordick F, Link T, Schwaiger M, Siewert JR, Weber WA (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 21(24):4604–4610. doi:10.1200/JCO.2003.06.574

    Article  PubMed  CAS  Google Scholar 

  26. Grundei T, Vogelsang H, Ott K, Mueller J, Scholz M, Becker K, Fink U, Siewert JR, Hofler H, Keller G (2000) Loss of heterozygosity and microsatellite instability as predictive markers for neoadjuvant treatment in gastric carcinoma. Clin Cancer Res 6(12):4782–4788

    PubMed  CAS  Google Scholar 

  27. Mutze K, Langer R, Becker K, Ott K, Novotny A, Luber B, Hapfelmeier A, Gottlicher M, Hofler H, Keller G (2010) Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer. Ann Surg Oncol 17:3336–3343. doi:10.1245/s10434-010-1182-1

    Article  PubMed  Google Scholar 

  28. Napieralski R, Ott K, Kremer M, Becker K, Boulesteix AL, Lordick F, Siewert JR, Hofler H, Keller G (2007) Methylation of tumor-related genes in neoadjuvant-treated gastric cancer: relation to therapy response and clinicopathologic and molecular features. Clin Cancer Res 13(17):5095–5102. doi:10.1158/1078-0432.CCR-07-0241

    Article  PubMed  CAS  Google Scholar 

  29. Ott K, Lordick F, Becker K, Ulm K, Siewert J, Hofler H, Keller G (2008) Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients. Int J Colorectal Dis 23(8):773–782. doi:10.1007/s00384-008-0490-4

    Article  PubMed  Google Scholar 

  30. Ott K, Vogelsang H, Marton N, Becker K, Lordick F, Kobl M, Schuhmacher C, Novotny A, Mueller J, Fink U, Ulm K, Siewert JR, Hofler H, Keller G (2006) The thymidylate synthase tandem repeat promoter polymorphism: a predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer. Int J Cancer 119(12):2885–2894. doi:10.1002/ijc.22235

    Article  PubMed  CAS  Google Scholar 

  31. Ott K, Vogelsang H, Mueller J, Becker K, Muller M, Fink U, Siewert JR, Hofler H, Keller G (2003) Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin Cancer Res 9(6):2307–2315

    PubMed  CAS  Google Scholar 

  32. Siewert JR, Bottcher K, Stein HJ, Roder JD, Busch R (1995) Problem of proximal third gastric carcinoma. World J Surg 19(4):523–531

    Article  PubMed  CAS  Google Scholar 

  33. Ott K, Bader FG, Lordick F, Feith M, Bartels H, Siewert JR (2009) Surgical factors influence the outcome after Ivor-Lewis esophagectomy with intrathoracic anastomosis for adenocarcinoma of the esophagogastric junction: a consecutive series of 240 patients at an experienced center. Ann Surg Oncol 16(4):1017–1025. doi:10.1245/s10434-009-0336-5

    Article  PubMed  Google Scholar 

  34. Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW, Coit DG, Brennan MF (2007) Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg 246(1):1–8. doi:10.1097/01.sla.0000255563.65157.d2

    Article  PubMed  Google Scholar 

  35. Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L (1999) Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 230(2):170–178

    Article  PubMed  CAS  Google Scholar 

  36. Gouzi JL, Huguier M, Fagniez PL, Launois B, Flamant Y, Lacaine F, Paquet JC, Hay JM (1989) Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg 209(2):162–166

    Article  PubMed  CAS  Google Scholar 

  37. Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JT, van Elk P, Obertop H, Gouma DJ, Taat CW et al (1995) Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 345(8952):745–748

    Article  PubMed  CAS  Google Scholar 

  38. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M, Fayers P (1999) Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 79(9–10):1522–1530. doi:10.1038/sj.bjc.6690243

    Article  PubMed  CAS  Google Scholar 

  39. Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, Welvaart K, van Krieken JH, Meijer S, Plukker JT, van Elk PJ, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H, Sasako M (2004) Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 22(11):2069–2077. doi:10.1200/JCO.2004.08.026

    Article  PubMed  CAS  Google Scholar 

  40. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K (2008) D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359(5):453–462. doi:10.1056/NEJMoa0707035

    Article  PubMed  CAS  Google Scholar 

  41. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, Lui WY, Whang-Peng J (2006) Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 7(4):309–315. doi:10.1016/S1470-2045(06)70623-4

    Article  PubMed  CAS  Google Scholar 

  42. Yun M, Lim JS, Noh SH, Hyung WJ, Cheong JH, Bong JK, Cho A, Lee JD (2005) Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT. J Nucl Med 46(10):1582–1588

    PubMed  Google Scholar 

  43. Chen J, Cheong JH, Yun MJ, Kim J, Lim JS, Hyung WJ, Noh SH (2005) Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer 103(11):2383–2390. doi:10.1002/cncr.21074

    Article  PubMed  Google Scholar 

  44. Kim SK, Kang KW, Lee JS, Kim HK, Chang HJ, Choi JY, Lee JH, Ryu KW, Kim YW, Bae JM (2006) Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging 33(2):148–155. doi:10.1007/s00259-005-1887-8

    Article  PubMed  Google Scholar 

  45. Mukai K, Ishida Y, Okajima K, Isozaki H, Morimoto T, Nishiyama S (2006) Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer 9(3):192–196. doi:10.1007/s10120-006-0374-7

    Article  PubMed  Google Scholar 

  46. Siewert JR, Bottcher K, Stein HJ, Roder JD (1998) Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 228(4):449–461

    Article  PubMed  CAS  Google Scholar 

  47. Siewert JR, Bottcher K, Roder JD, Busch R, Hermanek P, Meyer HJ (1993) Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg 80(8):1015–1018

    Article  PubMed  CAS  Google Scholar 

  48. Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW, Coit DG, Brennan MF (2007) Lymphadenectomy for adenocarcinoma of the gastroesophageal junction (GEJ): impact of adequate staging on outcome. Ann Surg Oncol 14(2):306–316. doi:10.1245/s10434-006-9166-x

    Article  PubMed  Google Scholar 

  49. Marchet A, Mocellin S, Ambrosi A, Morgagni P, Garcea D, Marrelli D, Roviello F, de Manzoni G, Minicozzi A, Natalini G, De Santis F, Baiocchi L, Coniglio A, Nitti D (2007) The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients. Ann Surg 245(4):543–552. doi:10.1097/01.sla.0000250423.43436.e1

    Article  PubMed  Google Scholar 

  50. Schuhmacher C, Novotny A, Ott K, Feith M, Siewert JR (2007) [Lymphadenectomy with tumors of the upper gastrointestinal tract]. Chirurg 78(3):203–206. doi:10.1007/s00104-007-1307-7, 208–212, 214–206

    Article  PubMed  CAS  Google Scholar 

  51. Ott K, Lordick F, Herrmann K, Krause BJ, Schuhmacher C, Siewert JR (2008) The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer 11(1):1–9. doi:10.1007/s10120-007-0448-1

    Article  PubMed  Google Scholar 

  52. Yoshioka T, Yamaguchi K, Kubota K, Saginoya T, Yamazaki T, Ido T, Yamaura G, Takahashi H, Fukuda H, Kanamaru R (2003) Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med 44(5):690–699

    PubMed  CAS  Google Scholar 

  53. Bonenkamp JJ, Songun I, Hermans J, van de Velde CJ (1996) Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer. Br J Surg 83(5):672–674

    Article  PubMed  CAS  Google Scholar 

  54. Hundahl SA, Peeters KC, Kranenbarg EK, Hartgrink H, van de Velde CJ (2007) Improved regional control and survival with “low Maruyama Index” surgery in gastric cancer: autopsy findings from the Dutch D1-D2 Trial. Gastric Cancer 10(2):84–86. doi:10.1007/s10120-007-0426-7

    Article  PubMed  Google Scholar 

  55. Peeters KC, Hundahl SA, Kranenbarg EK, Hartgrink H, van de Velde CJ (2005) Low Maruyama index surgery for gastric cancer: blinded reanalysis of the Dutch D1-D2 trial. World J Surg 29(12):1576–1584. doi:10.1007/s00268-005-7907-9

    Article  PubMed  CAS  Google Scholar 

  56. Sasako M, Sano T, Yamamoto S, Sairenji M, Arai K, Kinoshita T, Nashimoto A, Hiratsuka M (2006) Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 7(8):644–651. doi:10.1016/S1470-2045(06)70766-5

    Article  PubMed  Google Scholar 

  57. Stein HJ, Feith M, Siewert JR (2000) Cancer of the esophagogastric junction. Surg Oncol 9(1):35–41. doi:S0960-7404(00)00021-9

    Article  PubMed  CAS  Google Scholar 

  58. Stein HJ, Feith M, Mueller J, Werner M, Siewert JR (2000) Limited resection for early adenocarcinoma in Barrett’s esophagus. Ann Surg 232(6):733–742

    Article  PubMed  CAS  Google Scholar 

  59. Wang XB, Yang LT, Zhang ZW, Guo JM, Cheng XD (2008) Pancreaticoduodenectomy for advanced gastric cancer with pancreaticoduodenal region involvement. World J Gastroenterol 14(21):3425–3429

    Article  PubMed  Google Scholar 

  60. Wu CW, Chang IS, Lo SS, Hsieh MC, Chen JH, Lui WY, Whang-Peng J (2006) Complications following D3 gastrectomy: post hoc analysis of a randomized trial. World J Surg 30(1):12–16. doi:10.1007/s00268-005-7951-5

    Article  PubMed  Google Scholar 

  61. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S (2010) Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 28(9):1547–1553. doi:10.1200/JCO.2009.25.4706

    Article  PubMed  CAS  Google Scholar 

  62. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, Bredenkamp R, Hofler H, Fink U, Peschel C, Schwaiger M, Siewert JR (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8(9):797–805. doi:10.1016/S1470-2045(07)70244-9

    Article  PubMed  Google Scholar 

  63. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Bottcher K, Siewert JR, Hofler H (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98(7):1521–1530. doi:10.1002/cncr.11660

    Article  PubMed  Google Scholar 

  64. Park JO, Lee SI, Song SY, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Lee KS, Park K (2003) Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 33(10):533–537

    Article  PubMed  Google Scholar 

  65. Yoshida S, Miyata Y, Ohtsu A, Boku N, Shirao K, Shimada Y (2000) Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer. Gastric Cancer 3(3):128–133

    Article  PubMed  Google Scholar 

  66. Burge ME, Smith D, Topham C, Jackson DP, Anthoney DA, Halstead F, Seymour MT (2006) A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. Br J Cancer 94(9):1281–1286. doi:10.1038/sj.bjc.6603084

    Article  PubMed  CAS  Google Scholar 

  67. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G et al (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73(11):2680–2686

    Article  PubMed  CAS  Google Scholar 

  68. Shah MA, Yeung H, Coit D, Trocola R, Ilson D, Randazzo J, Tang L, Brennan M, Divgi C, Kelsen DP (2007) A phase II study of preoperative chemotherapy with irinotecan (CPT) and cisplatin (CIS) for gastric cancer(NCI 5917): FDG-PET/CT predicts patient outcome. ASCO Meeting Abstracts 25(18_suppl):4502

    Google Scholar 

  69. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschlager G, Busch R, Siewert JR, Schwaiger M, Fink U (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19(12):3058–3065

    PubMed  CAS  Google Scholar 

  70. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M, Siewert JR (2006) Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24(29):4692–4698. doi:10.1200/JCO.2006.06.7801

    Article  PubMed  Google Scholar 

  71. Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, Goldberg M (2005) Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23(19):4330–4337. doi:10.1200/JCO.2005.05.017

    Article  PubMed  Google Scholar 

  72. Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K (2004) Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg 28(3):247–253. doi:10.1007/s00268-003-7191-5

    Article  PubMed  Google Scholar 

  73. Arnott SJ, Duncan W, Gignoux M, Hansen HS, Launois B, Nygaard K, Parmar MK, Rousell A, Spilopoulos G, Stewart G, Tierney JF, Wang M, Rhugang Z (2005) Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev (4):CD001799. doi:10.1002/14651858.CD001799.pub2

  74. Bader FG, Lordick F, Fink U, Becker K, Hofler H, Busch R, Siewert JR, Ott K (2008) Paclitaxel in the neoadjuvant treatment for adeno carcinoma of the distal esophagus (AEG I). A comparison of two phase II trials with long-term follow-up. Onkologie 31(7):366–372. doi:10.1159/000135515

    Article  PubMed  CAS  Google Scholar 

  75. Kameyama R, Yamamoto Y, Izuishi K, Takebayashi R, Hagiike M, Murota M, Kaji M, Haba R, Nishiyama Y (2009) Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 36(3):382–388. doi:10.1007/s00259-008-0970-3

    Article  PubMed  Google Scholar 

  76. Lorenzen S, Panzram B, Keller G, Lordick F, Herrmann K, Becker K, Langer R, Schwaiger M, Siewert JR, Ott K (2010) Association of the VEGF 936C> T polymorphism with FDG uptake, clinical, histopathological, and metabolic response in patients with adenocarcinomas of the esophagogastric junction. Mol Imaging Biol. doi:10.1007/s11307-010-0330-0

  77. Lordick F, Ott K, Novotny A, Schuhmacher C, Siewert JR (2007) R1 resection in the surgery of upper gastrointestinal tumors: relevance and therapeutic consequences. Chirurg 78(9):792–801. doi:10.1007/s00104-007-1381-x

    Article  PubMed  CAS  Google Scholar 

  78. D’Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS (2004) Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 240(5):808–816. doi:00000658-200411000-00012

    Article  PubMed  Google Scholar 

  79. Siewert JR, Lordick F, Ott K, Brucher BL, Rosenberg R (2006) Curative vs palliative strategies in locoregional recurrence of gastrointestinal malignancies. Chirurg 77(3):227–235. doi:10.1007/s00104-006-1163-x

    Article  PubMed  CAS  Google Scholar 

  80. Siewert JR, Lordick F, Ott K, Stein HJ, Weber WA, Becker K, Peschel C, Fink U, Schwaiger M (2007) Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome. Ann Surg 246(4):624–628. doi:10.1097/SLA.0b013e318155a7d1, discussion 628–631

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Surgery, University of Heidelberg, INF 110, 69120, Heidelberg, Germany

    Katja Ott, Susanne Blank & Markus Büchler

  2. Department of Medicine, Klinikum Braunschweig, Hannover Medical School, Hannover, Germany

    Florian Lordick

Authors
  1. Katja Ott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Florian Lordick
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susanne Blank
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Markus Büchler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katja Ott.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ott, K., Lordick, F., Blank, S. et al. Gastric cancer: surgery in 2011. Langenbecks Arch Surg 396, 743–758 (2011). https://doi.org/10.1007/s00423-010-0738-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00423-010-0738-7

Keywords

Search

Navigation